PATH-15. IDENTIFICATION OF SUBSETS OF IDH-MUTANT GLIOBLASTOMAS WITH DISTINCT EPIGENETIC AND COPY NUMBER ALTERATIONS AND STRATIFIED CLINICAL RISKS

Eitemau Tebyg

• Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks
  gan: Li, Kay Ka-Wai, et al.
  Cyhoeddwyd: (2019)
• PATH-42. IDH-MUTANT LOWER-GRADE ASTROCYTOMAS CAN BE STRATIFIED FOR RISK BY CDKN2A, CDK4 AND PDGFRA COPY NUMBER ALTERATIONS
  gan: Rui Yang, Ryan, et al.
  Cyhoeddwyd: (2019)
• Combined epigenetic signature and gene copy number variations in IDH-mutant glioblastomas showed varied risk stratification
  gan: Keung Ng, Ho, et al.
  Cyhoeddwyd: (2019)
• PATH-02. A COMBINATION OF MGMT METHYLATION AND NFKBIA COPY NUMBER ALTERATION REFINES PROGNOSTICATION OF IDH-WT GLIOBLASTOMAS
  gan: Umehara, Toru, et al.
  Cyhoeddwyd: (2019)
• PATH-23. GENOMIC LANDSCAPE OF IDH-MUTANT PRIMARY GLIOBLASTOMAS SHOWS DISTINCT CLINICAL AND MOLECULAR FEATURES AND THAT CDKN2A SHOULD BE SUPPLEMENTED WITH MGMTp AND G-CIMP FOR PRECISE PROGNOSTICATION
  gan: Wong, Queenie Hoi-Wing, et al.
  Cyhoeddwyd: (2020)